News

IMS Health Acquires AlphaImpactRx (AIRx)

February 3, 2016 

With the addition of AIRx, IMS Health is acquiring complementary offerings, capabilities and technologies to increase speed-to-insight and drive performance.

Click to read article


Barclays
I/O Headache for fast-followers

January 27, 2016 

Opdivo’s dominance in lung cancer raises key commercial questions while Keytruda maintains melanoma leadership despite increasing pressure.

Click to read article


Barclays
Novartis
It’s an uphill climb to the bottom

January 18, 2016 

Cosentyx and Entresto are estimated (company provided consensus) to deliver a combined $1.5bn in sales in 2016. Barclays proprietary data suggests that is a tough ask.

Click to read article


The Evolving Role of PD-L1 Testing in Immunotherapy of Metastatic Melanoma and Non-Small Cell Lung Cancer

December 17, 2015

This article looks closely at the PD-L1 biomarker and its influence to date on the usage of PD-1 inhibitors.

Click to read more


 

AlphaImpactRx and Barclays Capital Webinar on Immuno-Oncology and Emerging Market Dynamics

December 2, 2015

To advance your understanding of the unprecedented changes emerging across promotion, treatment and testing - and to provide a view into how 2016 is shaping up.

Click to read more


Barclays U.S. Major Pharmaceuticals: Opdivo/Keytruda Heading into Q3

October 23, 2015

Is Opdivo/Keytruda rapidly becoming the standard of care, does this provide an important first-mover advantage? Prescribing data from AlphaImpactRx highlight that the adoption of Opdivo and Keytruda has been very rapid, with the two drugs combined capturing 61% and 71% of the on-label indications in refractory melanoma and squamous NSCLC, respectively. 

Barclays-US-Major-Pharmaceuticals-OpdivoKeytruda-heading-into-Q3.pdf 


 

Barclays Global Pharmaceuticals: The Tortoise and the Hare

August 19, 2015

Will the rapid adoption of BMY’s Opdivo and MRK’s Keytruda in melanoma and refractory lung cancer be enough to meet revenue expectations?  Proprietary prescribing data from AlphaImpactRx highlights that the adoption of Opdivo and Keytruda has been very rapid, with the two drugs combined capturing 75% and 63% of the on-label indications in refractory melanoma and squamous NSCLC, respectively.

Barclays-Global-Pharmaceuticals-The-Tortoise-and-the-Hare.pdf


 

Barclays - The IO Battlefield: How Are Opdivo and Keytruda Doing In The Marketplace?

June 22, 2015

One of the key conclusions from ASCO 2015 was that the immuno-oncology battlefield is becoming increasingly competitive behind the US launches of BMY’s Opdivo and MRK’s Keytruda.  Key questions for Barclays Capital during the early roll-out phase of these assets include who is winning in the battle between Opdivo and Keytruda in melanoma and how quickly has Opdivo gained traction in lung cancer?  These questions were addressed using proprietary data from AlphaImpactRx on a Barclays conference call held at 10am EST on Monday, June 22.

Click to read the full article


 

AlphaImpactRx Ranked in Top-Half of 2015 AMA Gold Top 50 Report

June, 2015

First Report conducted by CASRO, in partnership with AMA, ranks AlphaImpactRx 22nd in US revenues among the top 50 US-based market research firms; highest-ranked newcomer to the Report. 

Click to read the full article



AlphaImpactRx Launches BrandImpactDx

June 16, 2015

New offering extends the value of BrandImpact to deliver unique insight into the usage of molecular diagnostic tests in Oncology from a robust sample of oncologists and pathologists in near real-time through a cloud-based reporting and analytics platform.

Click to read the full article



AlphaImpactRx Launches BrandImpact Global Diabetes

June 4, 2015

Global offering fueled by new longitudinal mobile research panels in the EU and Japan is designed to provide clear and consistent visibility into diabetes brand performance across and within key international markets.

Click to read the full article


 

Key Topics of Interest for Oncologists Attending 2015 ASCO

May 26, 2015

2015 ASCO Conference
Which Topics Are Sparking Interest?

Click to read the full article


 

AlphaImpactRx Appoints Darrell Philpot Senior Vice President, Analytics and Chief Methodologist

May 12, 2015

Former Adheris Health and IMS Health analytics leader strengthens management team with his extensive experience in survey sampling, statistical modeling and solutions development.

Click to read the full article


5th Annual Outlook on the Biopharmaceutical Promotional Landscape in Oncology: Evolving Sales Models and Promotional Effectiveness

February 19, 2015

AlphaImpactRx has collaborated with Oncology Business Review to generate the latest installment of our annual year-end review of the personal promotional landscape in oncology. This overview of promotional trends will be supplemented with insights into the approaches companies are undertaking to maximize the value of their sales representatives. 

Click to read the full article 


 

 

AlphaImpactRx formed from the spin-out of AlphaDetail and ImpactRx; new company will focus on delivering comprehensive market research services and unique primary research-based insights to the marketplace.

January 7, 2015

Symphony Technology Group (STG), a strategic private equity firm that focuses on building great companies that provide solutions combining content, analytics and SaaS software is happy to announce the spin-out of a new company, AlphaImpactRx, from our Symphony Health Solutions portfolio company.

AlphaImpactRx will offer comprehensive market research services to clients in the biopharmaceutical, medical device and consumer health spaces. The separation will enable both Symphony Health Solutions and AlphaImpactRx to better serve individual life sciences clients through increased focus on each company's core strategic and operational strengths.  After the spin-out, AlphaImpactRx will be the largest research services firm focused on biopharma in the US according to the AMA Gold Top 50 Report.

Three years ago when STG was beginning its journey in acquiring and building companies in the healthcare information content, analytics and software market, it started by putting all acquisitions under the Symphony Health Solutions banner, including highly respected brands such as ImpactRx, AlphaDetail and Source.

Over the last year, we’ve concluded that these businesses have different business models and management and operational needs, and that we will be able to provide the best value, innovation and service to our clients by separating into two distinct, focused businesses that work very closely together: Symphony Health Solutions, a leading provider of integrated patient-centric claims data, analytics and technology, and AlphaImpactRx, the leading provider of physician-centric primary market research, data and brand marketing solutions.

STG is fully committed to the success of both companies. Each will continue to invest in delivering the highest value to clients and they will continue partner to provide solutions integrating their unique assets to best fit the needs of our customers.

Our customers face increasingly complex challenges that require critical understanding of the drivers of market performance through all stages of the life cycle. We look forward to working more effectively under our new operating structure to help our customers make informed and timely business decisions to successfully navigate those challenges.

AlphaImpactRx will maintain office locations in Horsham, PA and San Mateo, CA.